Anixa Biosciences is trading at $3.21, up 5.07%, alongside a biotech-sector rally; no confirmed cause for the move is identified.
- The provided context reports XBI up 2.13%, alongside sharp gains in major U.S. indexes.
- On November 4, Anixa announced its ovarian cancer CAR-T trial will be presented at a December ESMO congress.
- The announcement also recapped prior trial progress, but no source explicitly linked it to the share-price move.